AZ, MSD's Koselugo is first EU therapy for neurofibromatosis

The European Commission has approved AstraZeneca and MSD's Koselugo for a rare genetic condition that causes tumours to develop on the covering of nerve cells, leading to disfigurement and

AstraZeneca, Merck cue up FDA verdict on selumetinib next ye...

Neurofibromatosis treatment granted orphan status by EMA

AstraZeneca and Merck & Co.